Top Markets
#1 Islamic Coin Islamic Coin +151.63%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.44%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.99%
#4 clBTC clBTC +12.10%
#5 OpenEden OpenEden +11.81%
#6 Arowana Arowana +9.99%
#7 Akedo Akedo +9.22%
#8 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.95%
#9 Mantle Staked Ether Mantle Staked Ether +8.55%
#10 MarsCoin MarsCoin +8.30%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFI
Rank in Stocks #40134
Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge,... Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
Share Price
$0.0039
Last synced: 2023-10-27
Market Cap
$235.97K
Change (1 day)
-13.33%
Change (1 year)
0.00%
Country
US
Trade Infinity Pharmaceuticals, Inc. (INFI)

Category

Healthcare
Operating Margin for Infinity Pharmaceuticals, Inc. (INFI)
Operating Margin as of 2026 TTM: 0.00%
According to Infinity Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Infinity Pharmaceuticals, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.